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Abstract
Investigators from academia and industry gathered on April 4 and 5, 2013, in Washington DC at the Arrowhead’s
2
nd Annual Cancer Immunotherapy Conference. Two complementary concepts were discussed: cancer “stem cells”
as targets and therapeutic platforms based on stem cells.
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The hotly debated existence of cancer “stem cells” (CSC)
or tumor-initiating cells (TIC) may have a tremendous
impact on the future of cancer treatment. As modern
oncology has thus far been largely unsuccessful in
achieving long-term management of cancer, identifying
and leveraging targets associated with tumor initiation,
relapse or metastasis is a rationale course of action. In
this regard, the field of oncology seems to be at an in-
flexion point: how do we identify and remove cancerous
cells responsible for disease relapse, metastasis, and
progression?
Unfortunately, CSCs seem to be quite refractory to
available therapeutic strategies. Since immunotherapy
offers mechanisms of action distinct from those of small
molecules and perhaps more amenable to quiescent
tumor cells, it has received significant interest as an alter-
nate therapeutic approach. In addition, the understanding
and utilization of normal hematopoietic and lymphoid
stem cells could open alternate avenues to more effectively
re-engineer and direct Tcells against CSCs.
To discuss these aspects, investigators from academia
and industry congregated in April 4 and 5 2013, in
Washington DC at the Arrowhead’s2
nd Annual Cancer
Immunotherapy Conference, dedicated to Stem Cells
and Cancer Immunotherapy. In brief, the theme of stem
cells has been approached in two complementary ways:
 Cancer “stem cells” as a new category of targets for
immune intervention, for both solid and
hematologic malignancies.
 Therapeutic platforms based on stem cells:
hematopoietic stem cells, reprogrammed pluripotent
stem cells, stem cell-like memory T cells and tumor-
derived stem cells.
This meeting was structured to start with research
topics followed by talks by industry representatives and
intermingled with workshop panels; however, this report
presents the main ideas in a different flow to help frame
the issues, discuss targets associated with cancer stem cells
and then close with applicable platform technologies.
Long term control of cancer and “cure” remain an
unmet medical need
Dr. William Matsui (Johns Hopkins University School
of Medicine) introduced elements of basic biology of
cancer stem cells, utilizing Multiple Myeloma as an ex-
ample. He conveyed the point that historically, the
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is based on the expectation that such therapies need to
show fairly rapid objective responses, manifested
through tumor regression. Endpoints that require long
term observation are being pursued only in late stage de-
velopment, but most of the oncology therapies approved
to date provide only incremental survival benefit despite
some impressive objective response rates. Thus, the
current drug development and regulatory strategies are
geared for drugs that show rapid evidence of tumor
shrinkage rather than substantially increased survival.
Inasmuch as there may be differential sensitivity of
tumor cell subsets with distinct biology within a cancer-
ous process, this is a significant flaw in the process of
drug development in oncology, since it could bias it
away from therapies that obliterate tumor initiating cells
or ‘cancer stem cells’. An alternative would be to test
drug candidates on tumor cell subsets with increased
clonogenic activity, which would accelerate the develop-
ment of drugs that reduce relapse rates and prolong sur-
vival by removing the tumor-initiating cells. Dr. Matsui
exemplified this model with findings of that CD19
+
CD138
–immunoglobulin-rearranged B cells carry the
hallmarks of ‘tumor initiating cells’ in multiple myeloma,
based on clonogenic analysis. This model of cancerous
stem cells with B cell-like phenotype in multiple mye-
loma, led to trials that evaluated rituximab (anti-CD20
mAb) as add on to chemotherapy. The outcome of this
evaluation raised the possibility that the CSCs in mul-
tiple myeloma are less differentiated (eg. CD19
+ CD20
-
cells), or that myeloma cells carry intrinsic clonogenic
properties.
New targets expressed on tumour initiating cells
are needed
Target identification and validation on “true” tumor-
initiating cells has been a key bottleneck. Optimal targets
should meet several characteristics: 1) expressed by can-
cerous cells; 2) expressed by tumorigenic cells (tumor-ini-
tiating cells or CSCs); 3) have a key role in tumor cell
biology; and 4) not expressed in normal cells or tissues. In
reality, the realm of the targets that meet these require-
ments is dismal, leading to significant efforts to identify
new targets amenable to immune interventions.
One such target that meets all these criteria appears to
be EGFRvIII, a truncated version of EGFR, endowed
with autonomous signalling and pro-tumorigenic cap-
abilities. Dr. Albert Wong from Stanford University
Medical Center described this target and its biology. He
summarized the evidence for EGFRvIII expression in
CSCs in glioblastoma, utilizing the in vitro spherule
assay. This supported the concept that in this disease,
the cells with the highest tumorigenic properties are
CD133 EGFRvIII double-positive cells. This renders
EGFRvIII, a neoantigen devoid of expression in normal
tissues, a quite appealing target for immune interven-
tions. Nevertheless, EGFRvIII is neither homogenously
expressed within tumors, nor it is indispensable as its ex-
pression could vary through various mechanisms during
tumor progression. In addition EGFRvIII and other EGFR
variants are expressed in various other tumor types. Cur-
rently, EGFRvIII is being pursued through vaccination
aimed to elicit specific antibodies, through monoclonal
antibodies and adoptive T cell therapy with genetically
engineered T cells expressing EGFRvIII-directed chimeric
antibody receptors (CARs).
Dr. Philip Greenberg from the University of Washington,
Fred Hutchinson Cancer Research Center, presented two
immunotherapeutic targets: a more recently described
target Cyclin A1, and an earlier discovered target that re-
ceived much attention to date, WT-1. He presented evi-
dence of expression of Cyclin A1 and WT-1 in Acute
Myeloid Leukemia (AML) CSCs, a cancer that is hier-
archically organized and amenable to therapeutic inter-
vention through targeting leukemogenic cells. These two
intra-cellular targets are also expressed in other cancers
including carcinomas. WT-1 is expressed at high levels
and quite homogenously in many different cancers, but
has some limited expression in normal cells such as stem
cells. A TCR-based adoptive T cell therapy encompassing
TCRs of certain affinities for the target MHC-peptide
complex could endow the engineered T cell with abilities
to recognize and affect cancerous rather than normal
cells. Cyclin A1 is a new and exciting target: while the
isoform Cyclin A2, derived from a closely related gene
CCNA2, is ubiquitously expressed during mitosis in nor-
mal cells, expression of Cyclin A1 encoded by CCNA1 is
largely restricted to the meiotic phase in normal germinal
cells but appears to be co-opted by many malignancies,
including ~60% of cases of AML. T cells against Cyclin
A1 and WT-1 epitopes were generated and tested in pre-
clinical models. Since these targets are amenable to TCR-
engineered adoptive T cell therapy, translational studies
are already ongoing, with clinical evaluation in AML pa-
tients with antigen expressing leukemia and the appropri-
ate HLA restricting element.
A target with a long research track record since its dis-
covery, chondroitin sulfate proteoglycan 4 (CSPG4), was
described by Dr. Soldano Ferrone (Massachusetts Gen-
eral Hospital and Harvard Medical School). He described
the major characteristics of this complex and extensively
glycosylated tumor antigen expressed on the cell mem-
brane. Based on its expression profile, CSPG4 is poten-
tially amenable to immune interventions such as antibody
therapy and chimeric antigen receptor (CAR)-engineered
T cells. CSPG4 is expressed on normal cells and highly
up regulated on tumor cells of various origin: ectodermic,
endodermic and mesodermic. Within tumors, CSPG4
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cells, supporting a multi-pronged mechanism of action.
The expression of CSPG4 on tumor initiating cells is of
major interest as this could facilitate more potent im-
mune interventions. CSPG4 expression on some normal
cells associated with vasculature and central nervous sys-
tem could be of concern; yet antibody based approaches
that exploit possible differential post-translational modifi-
cations yielding specific tumor associated epitopes, could
be a very fertile area of target identification and new drug
development.
A target with tumor-specific membrane expression
and thus amenable to antibody-based intervention is the
oncofetal protein 5T4. Normal expression of 5T4 also
known as trophoblast glycoprotein (TPGB) is limited to
placenta and embryonic stem cells. Expression of 5T4 is
observed in many carcinomas, and notably, its over-
expression in colorectal, gastric and ovarian cancers is
associated with advanced disease and/or worse clinical
outcome. 5T4 can function as a pro-migratory factor in
embryonic cells that have undergone an epithelial-to-
mesenchymal (EMT) transition and can also modulate
CXCR4 and Wnt signalling. Dr. Kenneth Geles of Pfizer
Inc. described the discovery that this well-known onco-
fetal protein is also enriched on cancer stem cells
(tumor-initiating cells) in non-small cell lung carcinoma
(NSCLC). In the H460 lung cancer cell line, the
CD24
low/CD44
high immunophenotype was determined
to be the more tumorigenic subpopulation of cells and
enriched for the 5T4 mRNA based on gene expression
profiling. Additionally, sorting cells from a NSCLC pa-
tient derived xenograft (PDX) based solely on 5T4 ex-
pression confirmed that 5T4
high cells were indeed more
tumorigenic than 5T4
low cells. In a primary NSCLC cul-
ture, 5T4 and markers of EMT were associated with an
undifferentiated phenotype analogous to embryonic stem
cells. Further, high levels of 5T4 expression were associ-
ated with poorly differentiated NSCLC tumors and
worse overall survival. Interestingly, treatment of pre-
clinical lung and breast cancer models with an anti-5T4
antibody drug conjugate (A1-mcMMAF) resulted in
long-term tumor regressions, a finding that has been
compelling enough to support the advancement of this
novel therapy to Phase 1 clinical trials. This is the first
proof-of-concept that targeting a heterogeneous subpop-
ulation of cells at the apex of a cellular hierarchy with
an ADC can inhibit tumor growth in preclinical models.
The biology of the target is critical as it could deter-
mine tumor escape mechanisms. Thus, targets associ-
ated with epithelial-mesenchymal transition (EMT)
could be very valuable as they offer an opportunity to
block tumor progression. Dr. Claudia Palena from the
National Cancer Institute presented a relatively new tar-
get Brachyury that is a T-box transcription factor,
intimately involved with EMT and associated with can-
cer cell stemness. Brachyury is an embryonically relevant
protein required for the normal development of the
mesoderm. While being absent in the majority of adult
normal tissues, with the exception of low levels detected
in normal testis and some thyroid tissues, Brachyury is
aberrantly expressed in various tumor types, including
lung, breast, colon and prostate carcinomas. Primary tu-
mors and metastatic lymph nodes and distant metastasis
of breast cancer have been shown to be highly positive
for the expression of Brachyury protein; in addition, high
levels of this transcription factor in primary breast tu-
mors associate with poor prognosis in tamoxifen-treated
patients. Expression of Brachyury in epithelial cancer
cells drives the phenomenon of tumor EMT, a pheno-
typic switch characterized by the loss of epithelial
markers, cell polarity and cell-to-cell contacts, and the
simultaneous gain of mesenchymal markers, tumor cell
motility, invasiveness and propensity to metastasize. Re-
cent investigations have demonstrated that tumor cells
undergoing EMT might also acquire features of stem-
like cells, including the ability to survive cytotoxic ther-
apies. In this regard, expression of Brachyury in lung
and breast carcinoma cells has been associated with
resistance to the cytotoxic effect of conventional anti-
cancer modalities, including chemotherapy and radi-
ation, both in vitro and in vivo. Due to its potentially
relevant role in tumor resistance and metastasis, target-
ing of Brachyury is being investigated as a novel anti-
tumor strategy. However, as a transcription factor,
Brachyury cannot be targeted with monoclonal anti-
bodies and the development of canonical small molecule
inhibitors against this kind of molecules has been so far
unsuccessful. It has been then proposed that a T-cell
mediated immunotherapeutic approach could be a viable
option to specifically eliminating tumor cells that ex-
press this transcription factor. In this regard, Brachyury
has been shown to be an immunogenic molecule; an
HLA-A0201 epitope was identified (WLLPGTSTL) and
used to efficiently expand Brachyury-specific CD8
+ T
cells from the blood of cancer patients, in vitro. The ex-
panded T-cell lines, more importantly, have been shown
to lyse tumor cells that endogenously express Brachyury.
Currently, various Brachyury-based cancer vaccine plat-
forms are being developed.
HER-2/Neu is a well characterized cell surface cell
growth receptor within the EGFR class of receptors, with
amplified expression, pronounced biological role in tu-
mors and strongly associated with breast and other car-
cinomas. Dr. Brian Czerniecki from the University of
Pennsylvania described the expression of HER-2 in
tumor cells with stem properties, with emphasis on
luminal breast cancer. Such stem cell-like cancer cells
co-expressing the estrogen receptor seem to have
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anisms of up-regulation rather than gene amplification.
Yet, they could be responsible for tumor relapse or pro-
gression. It is quite possible that such cells with rather
dim expression levels of Her-2, could have a prominent
role in tumor escape from targeted therapies irrespec-
tively of the Her-2 status of the tumor. Since it is known
that Her-2-directed antibody therapies are not applicable
or not effective in patients with tumors that have modest
levels of Her-2 expression, and that Her-2 positive patients
treated with Herceptin are still at risk to relapse, alternate
methods – such as immune interventions - to target such
cells are needed. To be effective, these methods need to
involve immune effectors that are capable to sense and
react to low levels of antigen (eg. T cells generated in vivo
through vaccination or generated ex vivo).
As mentioned above, another source of cancer stem
cell-associated targets is represented by glioblastoma,
one of the few solid tumors where there is quite convin-
cing evidence in support of the existence of such cells,
largely chemorefractory and radioresistant, and respon-
sible for tumor relapse. Dr. John Yu of Immunocellular
Therapeutics outlined the major characteristics of the
brain cancer stem cells and discussed targets amenable
to immune intervention against glioblastoma. Interest-
ingly, as this cancer originates from the ectoderm, its
shares quite a few antigens with melanoma. As these are
tissue differentiation antigens or cancer testes antigens,
with restricted expression within normal vital organs,
they constitute a rich source of novel targets amenable
to immunotherapy. An approach has been designed to
target such antigens by utilizing active immunotherapy
(therapeutic cancer vaccination) to elicit multiple im-
mune responses against several targets that yield domin-
ant epitopes expressed onto glioblastoma cells including
cancer stem cells. One of the key limitations of such an-
tigens is their intracellular expression, narrowing the
panel of applicable immune interventions. It remains to
be seen whether this concept could pave the way to a
commonly utilized approach to define epitopes-derived
from targets co-expressed by cancer stem.
Dr. Elaine Hurt from Medimmune described an
in vitro high throughput assay utilized in their labora-
tory to discover novel targets associated with cancer
stem cells, applicable to breast cancer and other tumor
types. These targets are amenable to antibody based
immunotherapy and related approaches, as they are
expressed on the cell membrane. She discussed the ra-
tionale supporting EZH2, a novel target associated with
the Wnt/Notch pathway, and thus closely related to
stemness. This assay and screening methodology carries
the promise of leading to identification of numerous
membrane borne targets associated with tumor initiat-
ing cells.
An appealing class of targets are those with expression
restricted to germinal cells and tumor tissues (Cancer
Testes Antigens, CTA). Unfortunately, the CTAs heavily
characterized to date are expressed inside the cell and thus
are targetable only through immunotherapies that are di-
rected at MHC-restricted epitopes, such as therapeutic
vaccines and TCR-engineered T cells. A key question is
whether there are CTAs with membrane expression also.
Dr. Maurizio Chiriva-Internati from Texas Tech Univer-
sity presented emerging evidence that certain CTAs, asso-
ciated with tumor initiating cells, can be also displayed
onto the cell membrane. SP17, AKAP4, Ropporin, and
PTTG1, recently and less characterized CTAs, present an
increased interest since they are expressed in a broad
range of tumors of widely different histological origin:
multiple myeloma, lung cancer, ovarian and prostate
carcinoma. AKAP4 in particular showed some promising
evidence of membrane expression onto the multiple mye-
loma cells, by both flowcytometric analysis and immuno-
histochemistry. The possible expression of some CTAs
onto the cell membrane, render these molecules promis-
ing targets for antibody and CAR-based approaches that
are not MHC restricted. This should be an area of intense
investigation as the number of targets identified to date
and amenable to powerful immunotherapies such as CAR
therapies, with expression strictly limited to tumor cells, is
very narrow.
In all, while much more needs to be done, the pro-
spect of identification of targets potentially associated
with cancer stem cells and amenable to immunotherapy,
is a catalyst to future discovery efforts and development
of therapies that could afford more durable control of
cancer.
Therapeutic strategies must effectively target
cancer stem cells
The second element of a therapy against cancer stem cells,
along with the appropriate target, is represented by the
therapeutic platform which could be a biological or a
small molecule capable to affect the viability or biological
properties of such cells (Figure 1). Immune interventions
are of particular interest as cancer stem cells or tumor ini-
tiating cells have a recognized refractoriness to conven-
tional therapies (chemotherapy, radiotherapy) and small
molecule targeted therapies. An immune mediated effect
could be less dependent on the metabolic or proliferative
state of the cells, and instead being linked to expression of
target antigens and immune modulating receptors.
The last decade or so witnessed an unprecedented
interest and progress with adoptive T cell therapy as a
means to engineer a competent immune system, and
thus render it capable to harness a cancerous process.
Dr. Philip Greenberg, from Fred Hutchinson Cancer
Research Center, introduced and described the key
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all its diverse embodiments, each with their advantages
and disadvantages. Three major elements must be con-
sidered to design safe and effective T cell therapies: 1) an
appropriate antigenic target; 2) generation of a high
avidity and high magnitude T cell response; and 3) the
ability of tumor-reactive T cells to infiltrate and retain
their function within the tumor microenvironment. Ef-
forts to manipulate the TCR affinity and avidity by sub-
stituting amino acid residues within the complementary
determining region 3 (CDR3) of the TCR chains, could
lead to greatly improved TCR-engineered T cells from
the point of view of efficacy. However, appropriate safe-
guards need to be pursued to pre-empt toxicities due to
cross-reactivity against unintended targets. As methods
to test for potential detrimental TCR cross-reactivity
with cells within normal tissues have been limited and
not adequately informative, this represents a hurdle for
utilization of affinity enhanced TCRs and of TCRs gen-
erated in preclinical models to be utilized in clinic that
requires the use of additional screening strategies. Other
aspects of adoptive cell transfer with TCR-engineered T
cells were also discussed: utilization of cytokines in the
manufacturing process, T cell subsets and vaccines to
enhance the effectiveness of adoptive T cell therapy and
T cell subsets for enhanced adoptive T cell therapy. A
cautionary note was provided relative to utilization of
central memory Tcells as a more globally efficacious Tcell
subset for immunotherapy, as there is emerging preclinical
evidence that the effectiveness of T cell subsets could be
dependent on the specific tumor that is targeted, probably
due to the constellation of immune modulating receptors
expressed within the tumor environment.
Dr. Richard Morgan from the National Cancer Insti-
tute presented the efforts of his group to design and test
genetically engineered Tcells encompassing chimeric anti-
gen receptors (CARs) against antigens such as EGFRvIII
and CSPG4. Such CARs are endowed with co-stimulatory
signalling domains that provide the engineered T cells
with supra-physiological capabilities. Dr. Morgan dis-
cussed their results obtained in a glioblastoma model, with
cancer stem cells in the neurosphere assay as targets for
an EGFRvIII-directed CAR engineered T cell approach.
These newer CARs complement a growing pipeline that
includes anti-CD19 CAR that showed objective clinical re-
sponses in leukemia and lymphoma. A third generation
CAR against EGFRvIII, encompassing 4-1BB, CD28,
CD3z as signalling domains, is currently undergoing phase
1 clinical testing in patients with relapsed glioblastoma
multiformae.
Dr. Daniel Powell from the University of Pennsylva-
nia presented his group’s efforts to design innovative T
cell based therapies for cancer, based on lentiviral gene
transfer to redirect human T cells against cancer anti-
gens via CARs. He introduced an innovative design of
an engineered T cell that could be armed ex vivo with
the desired ligand for a specific tumor target or targeted
against pre-labelled tumor cells in vivo, and is utilizable
as a universal therapeutic platform. Dr. Powell showed
the capacity of these universal immune receptor bearing
T cells to target a multiple and diverse tumor antigens,
including those expressed by cancer stem cells. The
Figure 1 Target characteristics and corresponding therapeutic approaches. This diagram outlines the major desirable characteristics of new
targets for immune interventions. Depending on expression pattern, such targets fall into two categories: 1) with membrane expression and thus
targetable by antibodies, antibody drug conjugates, bispecific antibodies/constructs, CAR-engineered T cells and certain vaccines that induce
antibodies; and 2) expressed inside the cells, and thus amenable to vaccines, tumor infiltrating lymphocytes, small molecules, re-programmed
T cells and NKT cells.
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receptor as the engineered T cells divide, however, this
might also be viewed as a built in safety switch to pre-
vent long term toxic effects of redirected T cells. Dr.
Powell also discussed approaches to increase on-tumor
immunity but limit off-tumor toxicity, by utilizing newer
CAR T cell designs based on simultaneous recognition
of multiple antigens. T cells co-expressing CARs that
recognize distinct antigens and are linked to signalling
motifs that would work efficiently in concert but not in-
dividually, could overcome a key limitation of currently
available targets: leaky expression on certain normal
cells. As an example, a dual CAR engineered T cell prod-
uct co-recognizing mesothelin and folate receptor is be-
ing considered for testing in patients with ovarian
carcinoma. Dr. Powell also discussed the significance of
signalling domains selected for CAR design, and pro-
vided compelling preclinical evidence that the CD27
costimulatory domain is a viable option to other signal-
ling domains such as the one borne by CD28. This work
also demonstrated an important, but previously un-
appreciated, role for CD27 signalling in the formation of
human T cell memory in vivo.
Dr. Masoud Manjili from Virginia Commonwealth
University School of Medicine, Massey Cancer Center
presented data relevant to the mechanism and applic-
ability of adoptive cellular therapy (ACT), in preclinical
models of breast carcinoma. He showed evidence that
reprogramming tumor-sensitized immune cells in the
presence of bryostatin 1/ionomycin and common gamma
chain cytokines, ex vivo, generated memory Tcells and ac-
tivated NKT/NK cell populations. Presence of activated
NKT/NK cells within the T cell product could have a
major role to its activity, through interfering with the im-
mune inhibiting role of the myeloid derived suppressor
cells (MDSCs). A key limitation of the adoptive T cell im-
munotherapy technology is the relatively short life-span of
functional T cells once they are infused into patients.
Tumor-induced suppression of T cells is another barrier
to effective immunotherapy of cancer. The use of activated
NKT/NK cells along with canonical long-lasting memory
T cells could tackle these two barriers. In addition, a con-
siderable effort is spent on creating and utilizing renew-
able sources of T cells by tapping into the potential of
normal hematopoietic and lymphoid stem cells.
In these lines, Dr. Nicholas Restifo, from the National
Cancer Institute, described his group’s pioneering efforts
in this area that led to discovery of stem cell-like mem-
ory T cells. Utilization of these cells for adoptive T cell
therapy could overcome current limitations, such as re-
duced engraftment, limited persistence of T cells and
need to preservation their functional capabilities over a
longer timeframe. Dr. Restifo outlined several ap-
proaches to increase the yield of stem cell-like T cells in
the manufacturing process of T cells for adoptive T cell
therapy, by manipulating the Wnt signalling pathway or
by utilizing certain cytokines that maintain the T cells in
a juvenile state. This strategy could be applied to both
tumor infiltrating lymphocytes (TILs) and receptor-
engineered T cells alike. In addition, he shared late-
breaking information on transcriptional and epigenetic
programming of T cell stemness, which could be utilized
to design approaches to de-differentiate such cells with
in vivo renewable capabilities, from effector T cells iso-
lated from tumors and other sources.
Dr. Richard Koya from University of California Los
Angeles presented his team’s activities in support of gen-
erating and testing hematopoietic stem cells engineered
with a TCR that recognizes NY-ESO-1, a well-known
cancer testes antigen. They showed successful differenti-
ation of functional CD8
+ T cells in humanized mice.
They so far successfully transduced human CD34+ cells
with an average transduction efficiency of 50% (0.5 to 1
viral copies per cell). At three months post-transplant in
a humanized NSG/HLA-A2 transgenic mouse model,
CD8+ T cells harvested from spleens could expand
in vitro and recognize NY-ESO-1 expressing targets, spe-
cifically killing melanoma cells. They also confirmed that
a co-expressed PET reporter gene sr39TK was functional
in vivo, as demonstrated by micro-PET imaging, and
that ganciclovir administration could efficiently elimin-
ate these cells. Dr. Koya outlined the plans to translate
these findings to a clinical trial that integrates 1) stem
cell transplantation with TCR-engineered hematopoietic
stem cells, 2) adoptive cell therapy with TCR-engineered
differentiated T cells, and 3) vaccination against NY-
ESO-1. In essence, purified CD34+ cells from mobilized
peripheral progenitor cells will be transduced with a
codon-optimized lentiviral vector to induce expression
of NY-ESO-1 TCR alpha and beta chains together with
the PET marker/suicide gene sr39Thymidine Kinase. This
novel clinical approach would allow continuous supply of
Tcells targeting a tumor antigen, addressing the issue seen
when injected mature tumor-targeted T cells start vanish-
ing from hosts by terminal differentiation.
Dr. Lili Yang, also from the University of California
Los Angeles, discussed her team’s efforts to engineer im-
munity through the utilization of genetically engineered
hematopoietic stem cells. She presented original findings
based on an innovative imaging technology applied to T
cells differentiated from TCR-engineered stem cells
engrafted into mice. Dr. Yang shared tantalizing evidence
that in this model, while differentiated CD8+ T cells mi-
grate to lymph nodes where they expand and persist, the
CD4+ T cells traffic to and persist within the lymphoid
tissue associated with the intestinal tract. She also pre-
sented the roles of IL-15 and IL-7 in the homeostasis
and survival of genetically engineered T cells that
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cells, to CD8+ and CD4+ T cells respectively.
In the current era of generation and manipulation of
human induced pluripotent stem cells (iPS), there is sig-
nificant and legitimate interest in understanding whether
one can utilize re-programmed iPS as a renewable
source of T cells for adoptive T cell therapy. Dr. Raul
Vizcardo from RIKEN Research Center for Allergy and
Immunology presented his group’s pioneering efforts to
generate high numbers of tumor-antigen specific T cells
from iPS de-differentiated from specific CD8
+ T cells
with proven anti-cancerous activity. Facilitated by tech-
niques to separate the most desirable Tcells from tumors,
this approach can revolutionize TIL-based adoptive T cell
therapy. Much more needs to be done to fully understand
and appropriately tap into this technology as a renewable
source of T cells with therapeutic potential, as well as to
understand its safety profile influenced by the presence of
undifferentiated cells.
Genetic cell engineering especially at the level of
lymphoid, hematopoietic or pluripotent stem cells car-
ries an inherent risk of oncogenesis. Dr. David Spencer
from Bellicum Pharmaceuticals, Inc. introduced the
CaspaCIDe™ system, which is a rapid, cell cycle-
independent and non-immunogenic suicide gene that is
triggered by the membrane-permeable, synthetic dimeri-
zer ligand, AP1903. Clinical proof of principle has been
demonstrated in a Phase I/II trial in the allogeneic,
hematopoietic stem cell therapy setting. Potential use of
CaspaCIDe to enable emerging stem cell therapies and
tumor-targeting T cells was also discussed. CaspaCIDe
comprises an FK506-binding protein 12 (FKBP12)-based,
high affinity (Kd ~0.1 nM) ligand-binding domain fused
to a truncated human Caspase-9 domain, lacking its
Caspase-recruitment domain (CARD). In the presence
of pM levels of AP1903, dimerization leads to its pro-
cessing and initiation of apoptosis within 30 minutes. In
the clinical setting symptoms of GVHD were alleviated
in less than 24 hours after administration of AP1903.
Outside of FKBP12v36 binding, the ligand is bio-inert
and is currently delivered as a single intravenous infu-
sion. This contrasts with the virally derived HSV-
thymidine kinase (tk)/, ganciclovir (GCV) system that is
already used to control some viruses, including cyto-
megalovirus, a major complication of bone-marrow
transplants. The HSV-tk/GCV system is also immuno-
genic, inappropriate for immune competent hosts and
relatively slow, requiring multiple infusions over several
days for maximum efficacy on cycling cells. The other
major, clinically promoted suicide gene therapy class, cell
surface proteins, like CD20 or truncated EGFRt coupled
with clinically approved antibodies, would be more lim-
ited by the diffusion characteristics of MoAbs and target
endogenous marker
+ cells as an unavoidable side effect.
A different platform technology that has been dis-
cussed comprises monoclonal antibodies that bind dir-
ectly to tumour initiating cells. Dr. Elaine Hurt of
Medimmune described some of her company’s efforts to
discover cancer stem cell-associated targets suitable for
antibody therapy. Dr. Soldano Ferrone of Harvard
Medical School and Dr. Kenneth Geles from Pfizer Inc.
presented their efforts on design, research and develop-
ment of antibodies in context of select targets – CSPG4
and 5T4 respectively – for treatment of various solid tu-
mours. More specifically, Dr. Geles described his team’s
efforts to develop an antibody drug conjugate (ADC)
against 5T4 comprising the tubulin inhibitor mono-
methylauristatin F, backed up by preclinical results in a
lung cancer model that lead to a phase 1 clinical trial.
At last but not least, another platform technology dis-
cussed at this meeting was active immunotherapy, or
therapeutic vaccines – spanning autologous dendritic
cells (DC) and other types of vectors. This approach is
aimed at inducing an immune response in the patient
against targets associated with cancer stem cells. If suc-
cessful, such an approach could be utilized to curb the
capability of tumours to establish metastasis or relapse
after standard treatment.
There were three DC-based therapeutic approaches
discussed. Dr. Brian Czerniecki of the University of
Pennsylvania described his group’s activities to develop a
HER-2 pulsed DC1 vaccine that is effective in inducing
CD4
+, CD8
+ T cell responses of T1 phenotype in 1)
HER-2 high expressing ductal carcinoma in situ (DCIS)
and early invasive breast cancer and 2) as well as inter-
mediate expressing HER-2 early luminal cancers. Such a
DC1 vaccine could eliminate HER-2 expressing DCIS
cells in the HER-2 2
+ population, compared with HER-2
high expressing early breast cancers. DC1 vaccines
against HER-2 may be useful adjuvants to eliminate
HER-2 expressing breast cancer stem cells that may be
responsible for many late recurrences in patients with
ER +luminal breast cancers. A trial to assess the DC1
vaccines in such patients after adjuvant therapy is being
currently conducted.
Dr. Andrew Cornforth, of California Stem Cell, Inc.
discussed the company’s progress utilizing their autolo-
gous stem cell based immunotherapy. This integrates an
innovative method to generate stem cell-like cells from
primary tumours, and utilization of autologous DC that
are pulsed with cancer stem cell antigens. Dr. Cornforth
discussed how the manufacturing challenges of autolo-
gous cell therapy products involving whole tumor cells
as an antigen source have been overcome by utilizing
proprietary techniques to purify and expand cancer stem
cells. In addition, he presented two phase II clinical trials
which demonstrated 5-year overall survival rates of 50%
in stage IV metastatic melanoma patients with many
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survival. Finally, he discussed the development of scale
up and scale out technologies while conducting a large,
multi-center phase III clinical trial.
Dr. John Yu of Immunocellular Therapeutics, pre-
sented the company’s focus on targeting brain cancer
stem cell-associated antigens, shared with the neural
crest, by utilizing peptide-pulsed DC vaccines. This pro-
gram is in phase 2 clinical development following
optimization of the vaccine formulation.
Dr. Claudia Palena from the NIH discussed in con-
text of the target Brachyury, a Phase I clinical trial of a
yeast recombinant vector encoding this protein, spon-
sored by Globimmune, which is currently ongoing in pa-
tients with advanced carcinomas. This vaccine platform,
consisting of heat-killed recombinant Saccharomyces
cerevisiae that expresses the full-length human Brachy-
ury protein has been developed through a collaborative
effort between the National Cancer Institute and Glo-
beImmune, and is currently undergoing Phase I clinical
testing in patients with advanced carcinomas.
As cancer stem cells are refractory to standard chemo-
therapy or radiotherapy, alternate immune based therap-
ies could be a more effective means to eliminate these
important cells and thereby attempt to control the
process of cancer relapse, metastasis, and facilitating
durable management of cancer. This is reflected by the
diversity of immune-therapeutic approaches currently
being tested to that aim, tailored to the characteristics of
the targets (Figure 2).
Closing remarks
In conclusion, the current drug development and regula-
tory strategies are geared for drugs that show rapid evi-
dence of tumor shrinkage rather than substantially
increased survival. Inasmuch as there may be differential
drug sensitivity of tumor cell subsets with distinct biol-
ogy within a cancerous process, this is a significant flaw
in the process of drug development in oncology, since it
could bias it away from therapies that obliterate tumor
initiating cells or ‘cancer stem cells’. An alternative
would be to test drug candidates on tumor cell subsets
with increased clonogenic activity, which would acceler-
ate the development of drugs that reduce relapse rates
and prolong survival by removing the tumor-initiating
cells. Dr. Matsui exemplified this model with findings of
that CD19
+ CD138
− immunoglobulin-rearranged B cells
carry the hallmarks of ‘tumor initiating cells’ in multiple
myeloma, based on clonogenic analysis. This model of
cancerous stem cells with B cell-like phenotype in
multiple myeloma, led to trials that evaluated rituxi-
mab (anti-CD20 mAb) as add on to chemotherapy.
The outcome of this evaluation raised the possibility
that the CSCs in multiple myeloma are less differentiated
Figure 2 Therapeutic approaches to target tumor-initiating or tumor-regenerating cells. The diagram presents the four major categories of
interventions potentially applicable: antibodies, vaccines, adoptive T cell therapy and small molecules.
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Targets Speaker Highlights
EGFRvIII Albert Wong,
Stanford University Medical Center
￿ Truncated version of EGFR, with autonomous signalling and pro-tumorigenic capabilities
￿ Expressed by CSCs in glioblastoma: the cells with the highest tumorigenic properties are CD133 EGFRvIII double-positive cells
￿ Neither homogenously expressed within tumors, nor indispensable to tumor cells; its expression could vary during tumor progression
￿ EGFRvIII is being pursued through vaccination, monoclonal antibodies and adoptive T cell therapy with CARs
Cyclin A1Wilms Tumor
antigen -1 (WT-1)
Philip Greenberg,
University of Washington,
Fred Hutchinson Cancer
Research Center
￿ Cyclin A1 and WT-1 are expressed in Acute Myeloid Leukemia (AML) CSCs
￿ Cyclin A1 is a new target: its expression encoded by CCNA1 is largely restricted to the meiotic phase in normal germinal cells but
appears to be co-opted by many malignancies, including ~60% of cases of AML
￿ T cells against Cyclin A1 and WT-1 epitopes were generated and tested in preclinical models
￿ Clinical evaluation of TCR-engineered adoptive T cell therapy is ongoing in AML patients with antigen
+ leukemia and the appropriate
HLA restricting element
Chondroitin sulfate
proteoglycan 4 (CSPG4)
Soldano Ferrone,
Massachusetts General Hospital
and Harvard Medical School
￿ Complex and extensively glycosylated tumor antigen expressed on the cell membrane
￿ Amenable to immune interventions such as antibody therapy and chimeric antigen receptor (CAR)-engineered T cells
￿ Expressed on normal cells and highly upregulated on tumor cells of various origin: ectodermic, endodermic and mesodermic
￿ Within tumors, CSPG4 could be also expressed on pericytes and other stromal cells, supporting a multi-pronged mechanism of action
￿ CSPG4 is also expressed on tumor initiating cells
￿ Its expression on some normal cells associated with vasculature and central nervous system could be of concern; yet antibody
approaches directed to post-translational modifications could be a fertile area of new drug development
5T4 -trophoblast
glycoprotein (TPGB)
Kenneth Geles, Pfizer Inc ￿ Tumor-specific membrane expression, amenable to antibody therapy. Normal expression of is limited to placenta and embryonic stem cells
￿ 5T4 is over-expressed in colorectal, gastric and ovarian cancers and is associated with advanced disease and/or worse clinical outcome
￿ It can function as a pro-migratory factor in embryonic cells that have undergone an epithelial-to-mesenchymal (EMT) transition and can
also modulate CXCR4 and Wnt signalling
￿ 5T4 is also enriched on cancer stem cells (tumor-initiating cells) in non-small cell lung carcinoma (NSCLC)
￿ In the H460 lung cancer cell line, the CD24
low/CD44
high subset is most tumorigenic and enriched for the 5T4 mRNA
￿ Sorting cells from a NSCLC patient derived xenograft (PDX) based on 5T4 expression confirmed that 5T4
high cells were more tumorigenic
￿ High levels of 5T4 expression were associated with poorly differentiated NSCLC tumors and worse overall survival
￿ Treatment of preclinical lung and breast cancer models with an anti-5T4 antibody drug conjugate (A1-mcMMAF) resulted in long-term
tumor regressions. This is the first proof-of-concept targeting a heterogeneous subpopulation of cells at the apex of a cellular hierarchy
with an ADC
￿ This therapeutic candidate entered Phase 1 clinical trials
B
o
t
e
t
a
l
.
J
o
u
r
n
a
l
f
o
r
I
m
m
u
n
o
T
h
e
r
a
p
y
o
f
C
a
n
c
e
r
2
0
1
4
,
2
:
6
P
a
g
e
9
o
f
1
5
h
t
t
p
:
/
/
w
w
w
.
i
m
m
u
n
o
t
h
e
r
a
p
y
o
f
c
a
n
c
e
r
.
o
r
g
/
c
o
n
t
e
n
t
/
2
/
1
/
6Table 1 Targets expressed on tumour initiating cells (Continued)
Brachyury Claudia Palena,
National Cancer Institute
￿ Brachyury is an embryonically relevant T-box protein required for the normal development of the mesoderm
￿ It is aberrantly expressed in various tumor types, including lung, breast, colon and prostate carcinomas
￿ Primary tumors, metastatic lymph nodes
￿ and distant metastasis of breast cancer have been shown to be highly positive for Brachyury
￿ Expression of Brachyury in epithelial cancer cells drives EMT. Tumor cells undergoing EMT acquire features of stemness
￿ Expression of Brachyury in lung and
￿ breast carcinoma cells has been associated with resistance to conventional anti-cancer modalities
￿ As antibodies are not applicable and small molecules have been unsuccessful, T-cell mediated immunotherapeutic approaches against
Brachyury are being developed
￿ Brachyury has been shown to be an immunogenic molecule; an HLA-A0201 epitope was identified (WLLPGTSTL) and used to efficiently
expand Brachyury-specific CD8+ T cells from patients
￿ Brachyury-based cancer vaccine is in clinical development
HER-2/Neu Brian Czerniecki,
University of Pennsylvania
￿ Well characterized cell surface, cell growth receptor within the EGFR class of receptors, with amplified expression and prominent biology
￿ Expressed on CSC in luminal breast cancer
￿ When co-expressed with the estrogen receptor, HER-2 expression is up-regulated by mechanisms other than gene amplification
￿ CSC with dim Her-2 expression could have a role in tumor escape from targeted therapies, irrespectively of the Her-2 status of the
primary tumor
￿ Her-2-directed antibody therapies are not applicable or not effective in patients with tumors that have modest levels of Her-2 expression
￿ Thus, alternate immune interventions to target such cells are needed, such as therapeutic vaccines, currently in development
EZH2 Elaine Hurt, Medimmune ￿ Described an in vitro high throughput assay to discover novel targets associated with cancer stem cells
￿ These targets are amenable to antibody based immunotherapy and related approaches, as they are expressed on the cell membrane
￿ Described EZH2, a novel target associated with the Wnt/Notch pathway, and thus closely related to stemness
Cancer testes
antigens (CTAs)
John Yu,
Immunocellular Therapeutics
￿ Another source of cancer stem cell-associated targets is represented by glioblastoma, with convincing evidence in support of their
existence
￿ These cells are largely chemorefractory and radioresistant, and responsible for tumor relapse
￿ As this cancer originates from the ectoderm, its shares antigens with melanoma. CTAs with restricted expression within normal vital
organs, constitute a rich source of novel targets amenable to immunotherapy
￿ An approach has been designed to target such antigens by utilizing active immunotherapy (therapeutic cancer vaccination) to elicit
multiple immune responses against glioblastoma cancer stem cells
Maurizio Chiriva-Internati,
Texas Tech University
￿ Most CTAs characterized to date are expressed inside the cell and thus are targetable only through immunotherapies that are directed
at MHC-restricted epitopes (therapeutic vaccines and TCR-engineered T cells)
￿ There is emerging evidence that certain CTAs, associated with tumor initiating cells, can be also displayed onto the cell membrane
￿ Such targets are SP17, AKAP4, Ropporin, and PTTG1, expressed in a broad range of tumors of widely different histological origin: multiple
myeloma, lung cancer, ovarian and prostate carcinoma
￿ AKAP4 in particular showed some promising evidence of membrane expression in multiple myeloma cells
￿ The possible expression of some CTAs onto the cell membrane, render these molecules promising targets for antibody and CAR-
approaches
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6Table 2 Therapeutic strategies to target cancer stem cells
Category Speaker Highlights
T cell receptor (TCR)
engineered T cells
Philip Greenberg,
Fred Hutchinson Cancer
Research Center
￿ Three major elements must be considered to design safe and effective T cell therapies: 1) an appropriate antigenic target; 2)
generation of a high avidity and high magnitude T cell response; and 3) the ability of tumor-reactive T cells to infiltrate and retain
their function within the tumor microenvironment
￿ Efforts to manipulate the TCR affinity and avidity by substituting amino acid residues within the complementary determining region
3 (CDR3) of the TCR chains, could lead to greatly improved TCR-engineered T cells from the point of view of efficacy
￿ However, appropriate safeguards need to be pursued to pre-empt toxicities due to cross-reactivity against unintended targets. This
represents a hurdle for utilization of affinity enhanced TCRs and of TCRs generated in preclinical models
￿ Other aspects of adoptive cell transfer with TCR-engineered T cells were also discussed: utilization of cytokines in the manufacturing
process, T cell subsets and vaccines to enhance the effectiveness of adoptive T cell therapy and T cell subsets for enhanced adoptive
T cell therapy
￿ Cautionary note was provided on using central memory T cells, as there is emerging preclinical evidence that the effectiveness of T
cell subsets could be dependent on the type of targeted tumor
Chimeric antibody receptor
(CAR)-engineered T cells
Richard Morgan,
National Cancer Institute
￿ Presented efforts to design and test genetically engineered T cells encompassing chimeric antigen receptors (CARs) against
antigens such as EGFRvIII and CSPG4
￿ Such CARs are endowed with co-stimulatory signalling domains that provide the engineered T cells with supra-physiological cap-
abilities￿ Discussed results obtained in a glioblastoma model, with cancer stem cells in the neurosphere assay as targets for an
EGFRvIII-directed CAR engineered T cell approach
￿ A third generation CAR against EGFRvIII, encompassing 4-1BB, CD28, CD3z as signalling domains, is currently undergoing phase 1
clinical testing in patients with glioblastoma multiformae
Daniel Powell,
University of Pennsylvania
￿ Introduced an innovative design of an engineered T cell that could be armed ex vivo with the desired ligand for a specific tumor
target or targeted against pre-labelled tumor cells in vivo (universal therapeutic platform)
￿ Such universal immune receptor bearing T cells can target multiple and diverse tumor antigens, including those expressed by
cancer stem cells
￿ The limitation of the approach could be the dilution of the receptor as the engineered T cells divide. However, this might also be
viewed as a built in safety switch to prevent long term toxic effects of redirected T cells
￿ Also discussed approaches to increase on-tumor immunity but limit off-tumor toxicity, by utilizing newer CAR T cell designs based
on simultaneous recognition of multiple antigens
￿ As an example, a dual CAR engineered T cell product co-recognizing mesothelin and folate receptor is being considered for testing
in patients with ovarian carcinoma
￿ Discussed the significance of signalling domains selected for CAR design, and provided compelling preclinical evidence that the
CD27 costimulatory domain is a viable option
Adoptive T+NKT/NK
cell therapy
Dr. Masoud Manjili,
Virginia Commonwealth
University School of Medicine,
Massey Cancer Center
￿ Presented data relevant to the mechanism and applicability of adoptive cellular therapy (ACT) in preclinical models of breast
carcinoma.
￿ Showed evidence that reprogramming tumor-sensitized immune cells in the presence of bryostatin 1/ionomycin and common
gamma chain cytokines, generated memory T cells and activated NKT/NK cell populations
￿ Presence of activated NKT/NK cells within the T cell product could have a major role, through interfering with immune inhibition
by the myeloid derived suppressor cells (MDSCs)
￿ The use of activated NKT/NK cells along with canonical long-lasting memory T cells could prolong the functionality of T cells and
overcome inhibiting mechanisms
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6Table 2 Therapeutic strategies to target cancer stem cells (Continued)
Stem cell like memory T cells
for adoptive T cell therapy
Nicholas Restifo,
National Cancer Institute
￿ Described his group’s pioneering efforts in this area that led to discovery of stem cell-like memory T cells
￿ Utilization of these cells for adoptive T cell therapy could overcome current limitations, such as reduced engraftment, limited
persistence of T cells and need to preservation their functional capabilities over a longer timeframe
￿ Outlined several approaches to increase the yield of stem cell-like T cells in the manufacturing process of T cells for adoptive T cell
therapy, by manipulating the Wnt signalling pathway or by utilizing certain cytokines that maintain the T cells in a juvenile state
￿ Shared late-breaking information on transcriptional and epigenetic programming of T cell stemness, which could be utilized to
design approaches to de-differentiate such cells with in vivo renewable capabilities, from effector T cells isolated from tumors and
other sources
Hematopoietic stem cells Richard Koya,
University of California
Los Angeles
￿ Presented generation and testing of hematopoietic stem cells engineered with a TCR that recognizes NY-ESO-1
￿ Showed successful differentiation of functional CD8+ T cells in humanized mice, from transduced human CD34+ cells with an
average transduction efficiency of 50%
￿ At three months post-transplant, CD8+ T cells harvested from spleens could expand in vitro and recognize NY-ESO-1 expressing
targets, specifically killing melanoma cells
￿ Also confirmed that a co-expressed PET reporter gene sr39TK was functional in vivo, as demonstrated by micro-PET imaging;
ganciclovir administration could efficiently eliminate these cells
￿ Outlined plans to translate these findings to a clinical trial that integrates 1) stem cell transplantation with TCR-engineered
hematopietic stem cells, 2) adoptive cell therapy with TCR-engineered differentiated T cells, and 3) vaccination
￿ In this trial, purified CD34+ cells from mobilized peripheral progenitor cells are transduced with a codon-optimized lentiviral vector
to induce expression of NY-ESO-1 TCR alpha and beta chains together with the PET marker/suicide gene
Lili Yang,
University of California
Los Angeles
￿ Discussed her team’s efforts to engineer immunity through the utilization of genetically engineered hematopoietic stem cells
￿ Presented results of an innovative imaging technology applied to T cells differentiated from TCR-engineered stem cells engrafted
into mice. Showed evidence that in this model, while differentiated CD8+ T cells migrate to lymph nodes where they expand and
persist, the CD4+ T cells traffic to and persist within the lymphoid tissue associated with the intestinal tract
￿ Discussed the roles of IL-15 and IL-7 in the homeostasis and survival of genetically engineered T cells that differentiate from
TCR-engineered hematopoietic stem cells, to CD8+ and CD4+ T cells respectively
Human induced pluripotent
stem cells (iPS)
Raul Vizcardo,
RIKEN Research Center for Allergy
and Immunology, Japan
￿ In the current era of generation and manipulation of, there is significant and legitimate interest in understanding whether one can
utilize re-programmed iPS as a renewable source of T cells for adoptive T cell therapy
￿ Presented pioneering efforts to generate high numbers of tumor-antigen specific T cells from iPS de-differentiated from specific
CD8+ T cells with proven anti-cancerous activity. Facilitated by techniques to separate the most desirable T cells from tumors, this
approach can revolutionize TIL-based adoptive T cell therapy
￿ Much more needs to be done to fully understand and appropriately tap into this technology as a renewable source of T cells with
therapeutic potential, as well as to understand its safety profile influenced by the presence of undifferentiated cells
CaspaCIDe™ system
(applicable to adoptive
cell therapy)
David Spencer,
Bellicum Pharmaceuticals Inc.
￿ Genetic cell engineering especially at the level of lymphoid, hematopoietic or pluripotent stem cells carries an inherent risk of
oncogenesis
￿ CaspaCIDe™ system is a rapid, cell cycle-independent and non-immunogenic suicide gene that is triggered by the membrane-
permeable, synthetic dimerizer ligand, AP1903
￿ Clinical proof of principle has been demonstrated in a Phase I/II trial in the allogeneic, hematopoietic stem cell therapy setting
￿ Potential use of CaspaCIDe to enable emerging stem cell therapies and tumor-targeting T cells was also discussed
￿ CaspaCIDe comprises an FK506-binding protein 12 (FKBP12)-based, high affinity (Kd~ 0.1 nM) ligand-binding domain fused to a
truncated human Caspase-9 domain, lacking its Caspase-recruitment domain (CARD). In the presence of pM levels of AP1903,
dimerization leads to its processing and initiation of apoptosis within 30 minutes
￿ In the clinical setting symptoms of
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6Table 2 Therapeutic strategies to target cancer stem cells (Continued)
￿ GVHD were alleviated in less than 24 hours after administration of AP1903
￿ Outside of FKBP12v36 binding, the ligand is bio-inert and is currently delivered as a single intravenous infusion
￿ This contrasts with the virally derived HSV-thymidine kinase (tk)/, ganciclovir (GCV) system that is immunogenic, inappropriate for
immune competent hosts, and relatively slow, requiring multiple infusions over several days for maximum efficacy on cycling cells
￿ The other major suicide gene therapy class, cell surface proteins, like CD20 or truncated EGFRt coupled with clinically approved
antibodies, would be more limited by the diffusion characteristics of MoAbs and possible co-targeting of normal cells
Monoclonal antibodies and
antibody drug conjugates
Elaine Hurt, Medimmune ￿ Described some of her company’s efforts to discover cancer stem cell-associated targets suitable for antibody therapy
Soldano Ferrone,
Harvard Medical School
￿ Presented efforts on design, research and develop antibodies against CSPG4 for treatment of various solid tumours
Kenneth Geles, Pfizer Inc. ￿ Described his team’s efforts to develop an antibody drug conjugate (ADC) against 5T4, comprising the tubulin inhibitor
monomethylauristatin F, backed up by preclinical results in a lung cancer model that lead to a phase 1 clinical trial
Therapeutic cancer vaccines Brian Czerniecki,
University of Pennsylvania
￿ Described his group’s activities to develop a HER-2 pulsed DC1 vaccine that is effective in inducing CD4, CD8 T cell responses of T1
phenotype in 1) HER-2 high expressing ductal carcinoma in situ (DCIS) and early invasive breast cancer and 2) as well as intermediate
expressing HER-2 early luminal cancers
￿ Such a DC1 vaccine could eliminate HER-2 expressing DCIS cells in the HER-2 2
+ population, compared with HER-2 high expressing
early breast cancers
￿ DC1 vaccines against HER-2 may be useful to eliminate HER-2 expressing breast cancer stem cells that may be responsible for many
late recurrences in patients with ER+ luminal breast cancers
￿ A trial to assess the DC1 vaccines in such patients after adjuvant therapy is being currently conducted
Andrew Cornforth,
of California Stem Cell, Inc.
￿ Discussed the company’s progress utilizing their autologous stem cell based immunotherapy. This integrates an innovative method
to generate stem cell-like cells from primary tumours, and utilization of autologous DC that are pulsed with cancer stem cell antigens
￿ Also discussed how the manufacturing challenges of autologous cell therapy products involving whole tumor cells as an antigen
source have been overcome by utilizing proprietary techniques to purify and expand cancer stem cells
￿ Presented two phase II clinical trials which demonstrated 5-year overall survival rates of 50% in stage IV metastatic melanoma
patients
￿ Discussed the development of scale up and scale out technologies while conducting a large, multi-center phase III clinical trial
John Yu,
Immunocellular Therapeutics Inc
￿ Presented the company’s focus on targeting brain cancer stem cell-associated antigens, shared with the neural crest, by utilizing
peptide-pulsed DC vaccines
￿ This program reached phase 2 clinical development following optimization of the vaccine formulation
Claudia Palena, NIH ￿ Discussed in context of the target Brachyury, a Phase I clinical trial of a yeast recombinant vector encoding this protein, sponsored
by Globimmune, in patients with carcinoma
￿ This vaccine platform, consisting of heat-killed recombinant Saccharomyces cerevisiae has been developed through a collaborative
effort between the National Cancer Institute and GlobeImmune
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6(eg. CD19
+ CD20
− cells), or that myeloma cells carry intrin-
sic clonogenic properties.
We can infer that optimal targets should meet several
characteristics: 1) expressed by cancerous cells; 2) ex-
pressed by tumorigenic cells (tumor-initiating cells or
CSCs); 3) have a key role in tumor cell biology; and 4) not
expressed in normal cells or tissues (Figure 1). In fact, the
current realm of the targets that meet these requirements
is dismal, leading to significant efforts to identify new
targets amenable to immune interventions. As target
identification and validation of expression by “true” tumor-
initiating cells has been a key bottleneck, many speakers
approached this subject, exemplifying it with specific
candidates or novel discovery strategies (Table 1).
The second element of a therapy against cancer stem
cells, along with the appropriate target, is represented by
therapeutic platforms which could be biologicals or
small molecules capable to affect the viability or bio-
logical properties of such cells (Figure 2). Immune inter-
ventions are of particular interest as cancer stem cells or
tumor initiating cells have a recognized refractoriness to
conventional therapies (chemotherapy, radiotherapy)
and small molecule targeted therapies. An immune me-
diated effect could be less dependent on the metabolic
or proliferative state of the cells, and instead being
linked to expression of target antigens and immune
modulating receptors. In light of the importance of this
topic, many of the speakers at this event reviewed and
discussed a broad range of immune therapeutic plat-
forms including but not limited to approaches based on
normal lymphoid stem cells (Table 2).
In conclusion, the concept of cancer stem cells re-
mains hotly debated but could be a fertile ground for
drug development, to address cancer resistance, relapse
and progression. Irrespectively of semantics and applic-
ability of the concept in a stricter or more relaxed fash-
ion across all tumor types, there seems to be clear that
the target cells of interest meet three key criteria:
1) Are relatively refractory to current therapies such as
chemotherapies, radiotherapy and small molecule
targeted therapies;
2) Can persist in the body for prolonged intervals in a
stealth mode, without being subjected to immune
surveillance or other homeostatic mechanisms;
3) Could re-generate the entire tumoral process usually
in an evolved, more clinically aggressive mode.
Based on these characteristics, we advance the concept
of “tumor regenerating cells” (TRC), as the subset of re-
sidual and resilient cancerous cells that mediate the
process of relapse and tumor progression (Figure 3).
These are the very target cells that should be in the
cross-hairs of drug development for cancer. They may
share features with, but do not need to recapitulate each
and every characteristics of stem cells.
Last but not least, industry started to take a keen
interest in cell based immune interventions to treat
cancer due to the prospect of objective and durable
clinical responses. Key, but addressable hurdles are the
complex biology and manufacturing of such thera-
peutics. Thus, the longer term questions are how to
define targets specifically associated with TRC, and
how to optimize immunotherapies to effectively elimin-
ate those cells thus achieving durable response or func-
tional cure.
Figure 3 Major characteristics of tumor-regenerating cells, a category of “cancer stem cells” that should be the focus of research and
development towards long term management of cancer.
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